Corient Private Wealth
DSGN icon

Corient Private Wealth’s Design Therapeutics DSGN Stock Holding History

Corient Private Wealth’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Hold
27,169
– – ﹤0.01% 2394
2026
Q1 		$289K Buy
27,169
+204
+0.8% +$2.06K ﹤0.01% 2333
2025
Q4 		$253K Buy
+26,965
New +$211K ﹤0.01% 2283
2025
Q3 		– Sell
-26,965
Closed -$90.9K – 2592
2025
Q2 		$90.9K Hold
26,965
– – ﹤0.01% 2343
2025
Q1 		$104K Hold
26,965
– – ﹤0.01% 2169
2024
Q4 		$166K Hold
26,965
– – ﹤0.01% 2163
2024
Q3 		$145K Hold
26,965
– – ﹤0.01% 2274
2024
Q2 		$90.3K Hold
26,965
– – ﹤0.01% 2222
2024
Q1 		$109K Buy
+26,965
New +$72K ﹤0.01% 2180

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Corient Private Wealth's DSGN Position: Q2 2026 in Review

Corient Private Wealth held its Design Therapeutics (DSGN) position steady in Q2 2026 at 27,169 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #2394.

Corient Private Wealth first reported a position in DSGN in Q1 2024 and has held it in 9 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Corient Private Wealth held 27,169 shares of Design Therapeutics worth $393K as of Q2 2026.
  • Corient Private Wealth left its Design Therapeutics share count unchanged in Q2 2026.
  • Design Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2394 holding.
  • Corient Private Wealth first reported a position in Design Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.